Does the media favor GOSS or ALLR?

In the previous week, Gossamer Bio and Gossamer Bio both had 2 articles in the media. Gossamer Bio's average media sentiment score of 0.92 beat Allarity Therapeutics' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer APLM or ALLR?

Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 935.35%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, APLM or ALLR?

Apollomics has higher revenue and earnings than Allarity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.64 -$10.94M N/A N/A Allarity Therapeutics $345K 45.66 -$11.23M -$0.78 N/A

Is APLM or ALLR more profitable?

Apollomics' return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Allarity Therapeutics N/A -152.77% -46.50%

Does the media favor APLM or ALLR?

In the previous week, Apollomics had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 3 mentions for Apollomics and 2 mentions for Allarity Therapeutics. Apollomics' average media sentiment score of 0.71 beat Allarity Therapeutics' score of 0.00 indicating that Apollomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ALLR or KVAC?

Allarity Therapeutics currently has a consensus target price of $10.25, suggesting a potential upside of 935.35%. Given Allarity Therapeutics' higher probable upside, research analysts clearly believe Allarity Therapeutics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, ALLR or KVAC?

Keen Vision Acquisition has lower revenue, but higher earnings than Allarity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allarity Therapeutics $345K 45.66 -$11.23M -$0.78 N/A Keen Vision Acquisition N/A N/A N/A N/A N/A

Is ALLR or KVAC more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -152.77% -46.50% Keen Vision Acquisition N/A N/A N/A

Is KLRS or ALLR more profitable?

Kalaris Therapeutics' return on equity of -71.71% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -71.71% -42.95% Allarity Therapeutics N/A -152.77% -46.50%

Does the media refer more to KLRS or ALLR?

In the previous week, Kalaris Therapeutics and Kalaris Therapeutics both had 2 articles in the media. Kalaris Therapeutics' average media sentiment score of 0.00 equaled Allarity Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALLR or PLRX more profitable?

Pliant Therapeutics' return on equity of -52.17% beat Allarity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -152.77% -46.50% Pliant Therapeutics N/A -52.17% -40.46%

Does the media favor ALLR or PLRX?

In the previous week, Pliant Therapeutics had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 3 mentions for Pliant Therapeutics and 2 mentions for Allarity Therapeutics. Pliant Therapeutics' average media sentiment score of 0.45 beat Allarity Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pliant Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Allarity Therapeutics (ALLR) Competitors

$0.99 +0.01 (+0.82%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+1.52%)

As of 10/9/2026 07:30 PM Eastern

Compare

ALLR vs. GOSS, APLM, KVAC, KLRS, and PLRX

Should you buy Allarity Therapeutics stock or one of its competitors? Allarity Therapeutics's main competitors and comparable companies include Gossamer Bio (GOSS), Apollomics (APLM), Keen Vision Acquisition (KVAC), Kalaris Therapeutics (KLRS), and Pliant Therapeutics (PLRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Allarity Therapeutics compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Gossamer Bio has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 4.2% of Gossamer Bio shares are held by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Allarity Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Allarity Therapeutics	N/A	-152.77%	-46.50%

Allarity Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	1.17	-$170.37M	-$56.00	N/A
Allarity Therapeutics	$345K	45.66	-$11.23M	-$0.78	N/A

In the previous week, Gossamer Bio and Gossamer Bio both had 2 articles in the media. Gossamer Bio's average media sentiment score of 0.92 beat Allarity Therapeutics' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gossamer Bio currently has a consensus price target of $256.00, indicating a potential upside of 2,649.73%. Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 935.35%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Gossamer Bio is more favorable than Allarity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Gossamer Bio beats Allarity Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Allarity Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLM) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Apollomics has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 935.35%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Apollomics' return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Allarity Therapeutics	N/A	-152.77%	-46.50%

In the previous week, Apollomics had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 3 mentions for Apollomics and 2 mentions for Allarity Therapeutics. Apollomics' average media sentiment score of 0.71 beat Allarity Therapeutics' score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 0.2% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Apollomics has higher revenue and earnings than Allarity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.64	-$10.94M	N/A	N/A
Allarity Therapeutics	$345K	45.66	-$11.23M	-$0.78	N/A

Summary

Apollomics beats Allarity Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Allarity Therapeutics compare to Keen Vision Acquisition?

Allarity Therapeutics (NASDAQ:ALLR) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Allarity Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Keen Vision Acquisition has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

In the previous week, Allarity Therapeutics had 2 more articles in the media than Keen Vision Acquisition. MarketBeat recorded 2 mentions for Allarity Therapeutics and 0 mentions for Keen Vision Acquisition. Allarity Therapeutics' average media sentiment score of 0.00 equaled Keen Vision Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Allarity Therapeutics	Neutral
Keen Vision Acquisition	Neutral

Allarity Therapeutics currently has a consensus target price of $10.25, suggesting a potential upside of 935.35%. Given Allarity Therapeutics' higher probable upside, research analysts clearly believe Allarity Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Keen Vision Acquisition has lower revenue, but higher earnings than Allarity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$345K	45.66	-$11.23M	-$0.78	N/A
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Keen Vision Acquisition's return on equity of 0.00% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-152.77%	-46.50%
Keen Vision Acquisition	N/A	N/A	N/A

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Allarity Therapeutics beats Keen Vision Acquisition on 5 of the 9 factors compared between the two stocks.

How does Allarity Therapeutics compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Kalaris Therapeutics' return on equity of -71.71% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Allarity Therapeutics	N/A	-152.77%	-46.50%

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Kalaris Therapeutics and Kalaris Therapeutics both had 2 articles in the media. Kalaris Therapeutics' average media sentiment score of 0.00 equaled Allarity Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kalaris Therapeutics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

Allarity Therapeutics has higher revenue and earnings than Kalaris Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
Allarity Therapeutics	$345K	45.66	-$11.23M	-$0.78	N/A

Kalaris Therapeutics currently has a consensus target price of $18.75, indicating a potential upside of 694.49%. Allarity Therapeutics has a consensus target price of $10.25, indicating a potential upside of 935.35%. Given Allarity Therapeutics' higher probable upside, analysts clearly believe Allarity Therapeutics is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Kalaris Therapeutics beats Allarity Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Allarity Therapeutics compare to Pliant Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Allarity Therapeutics presently has a consensus target price of $10.25, suggesting a potential upside of 935.35%. Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 194.12%. Given Allarity Therapeutics' higher possible upside, equities analysts clearly believe Allarity Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pliant Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Allarity Therapeutics has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by company insiders. Comparatively, 8.7% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pliant Therapeutics' return on equity of -52.17% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-152.77%	-46.50%
Pliant Therapeutics	N/A	-52.17%	-40.46%

Allarity Therapeutics has higher earnings, but lower revenue than Pliant Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$345K	45.66	-$11.23M	-$0.78	N/A
Pliant Therapeutics	$1.58M	39.97	-$149.34M	-$1.49	N/A

In the previous week, Pliant Therapeutics had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 3 mentions for Pliant Therapeutics and 2 mentions for Allarity Therapeutics. Pliant Therapeutics' average media sentiment score of 0.45 beat Allarity Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allarity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pliant Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pliant Therapeutics beats Allarity Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Allarity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLR vs. The Competition

Export

Metric	Allarity Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.62M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-1.27	13.42	274.15	26.16
Price / Sales	45.66	1,234.32	589.97	94.50
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	1.62	17.17	11.21	6.34
Net Income	-$11.23M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-4.81%	-1.33%	-0.90%	-1.41%
1 Month Performance	-20.80%	-8.44%	-4.44%	-3.48%
1 Year Performance	-38.51%	14.02%	6.96%	1.16%

Allarity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLR Allarity Therapeutics	1.3935 of 5 stars	$0.99 +0.8%	$10.25 +935.4%	-43.8%	$15.62M	$345K	N/A	8
GOSS Gossamer Bio	2.6731 of 5 stars	$10.53 -2.3%	$256.00 +2,331.4%	-95.5%	$64.01M	$48.47M	N/A	162
APLM Apollomics	1.9383 of 5 stars	$21.97 -0.6%	N/A	+21.1%	$63.93M	$8.50M	N/A	15
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
KLRS Kalaris Therapeutics	2.0339 of 5 stars	$2.65 -0.4%	$18.75 +607.5%	-49.0%	$63.10M	N/A	N/A	20	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLR) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allarity Therapeutics (ALLR) Competitors

ALLR vs. GOSS, APLM, KVAC, KLRS, and PLRX

How does Allarity Therapeutics compare to Gossamer Bio?

Summary

How does Allarity Therapeutics compare to Apollomics?

Summary

How does Allarity Therapeutics compare to Keen Vision Acquisition?

Summary

How does Allarity Therapeutics compare to Kalaris Therapeutics?

Summary

How does Allarity Therapeutics compare to Pliant Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR vs. The Competition

Allarity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allarity Therapeutics (ALLR) Competitors

ALLR vs. GOSS, APLM, KVAC, KLRS, and PLRX

How does Allarity Therapeutics compare to Gossamer Bio?

Which has more risk & volatility, GOSS or ALLR?

Do institutionals & insiders have more ownership in GOSS or ALLR?

Is GOSS or ALLR more profitable?

Which has better valuation and earnings, GOSS or ALLR?

Does the media favor GOSS or ALLR?

Do analysts prefer GOSS or ALLR?

Summary

How does Allarity Therapeutics compare to Apollomics?

Which has more volatility and risk, APLM or ALLR?

Do analysts prefer APLM or ALLR?

Is APLM or ALLR more profitable?

Does the media favor APLM or ALLR?

Do institutionals & insiders believe in APLM or ALLR?

Which has better earnings & valuation, APLM or ALLR?

Summary

How does Allarity Therapeutics compare to Keen Vision Acquisition?

Which has more risk and volatility, ALLR or KVAC?

Does the media refer more to ALLR or KVAC?

Do analysts recommend ALLR or KVAC?

Which has stronger valuation & earnings, ALLR or KVAC?

Is ALLR or KVAC more profitable?

Do institutionals and insiders hold more shares of ALLR or KVAC?

Summary

How does Allarity Therapeutics compare to Kalaris Therapeutics?

Is KLRS or ALLR more profitable?

Do insiders & institutionals believe in KLRS or ALLR?

Does the media refer more to KLRS or ALLR?

Which has more risk and volatility, KLRS or ALLR?

Which has stronger valuation and earnings, KLRS or ALLR?

Do analysts prefer KLRS or ALLR?

Summary

How does Allarity Therapeutics compare to Pliant Therapeutics?

Do analysts recommend ALLR or PLRX?

Which has more volatility and risk, ALLR or PLRX?

Do institutionals and insiders hold more shares of ALLR or PLRX?

Is ALLR or PLRX more profitable?

Which has preferable valuation & earnings, ALLR or PLRX?

Does the media favor ALLR or PLRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLR vs. The Competition

Allarity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools